News Rare disease drug Strensiq too expensive, says NICE Alexion's new rare disease treatment Strensiq has been rejected by England's health watchdog NICE in draft guidance.
News Alexion must ‘explain’ high cost of Soliris, says NICE NICE has concluded that orphan drug Soliris is highly effective in treating rare disease aHUS – but says it won't approve the drug yet, asking pharma company Alexion to first 'explain' how
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
